VEGFA and idiopathic pulmonary fibrosis: For IPF management, pirfenidone and the triple tyrosine kinase [vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF)] inhibitor nintedanib are recommended to delay the progression of fibrosis, which cannot be reversed3.